IgD positive L&H cells identify a unique subset of nodular lymphocyte predominant Hodgkin lymphoma

American Journal of Surgical Pathology

Volumn 30, Issue 5, 2006, Pages 585-592

  Prakash, Sonam ^a   Fountaine, Thomas ^a   Raffeld, Mark ^a   Jaffe, Elaine S ^a   Pittaluga, Stefania ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

IgD; Nodular lymphocyte predominant Hodgkin lymphoma; PU.1; T cell histiocyte rich large B cell lymphoma

Indexed keywords

CD20 ANTIGEN; CD27 ANTIGEN; CD3 ANTIGEN; CD38 ANTIGEN; EPITHELIAL MEMBRANE ANTIGEN; IMMUNOGLOBULIN D; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; OCTAMER TRANSCRIPTION FACTOR 2; PROTEIN BCL 6; PROTEIN BOB 1; PROTEIN SWAP 70; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR PU 1; UNCLASSIFIED DRUG; TUMOR MARKER;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; B LYMPHOCYTE; CERVICAL LYMPH NODE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HISTIOCYTE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MALE; MEMORY CELL; NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA; SCHOOL CHILD; SEX DIFFERENCE; T LYMPHOCYTE; B CELL LYMPHOMA; BIOSYNTHESIS; CHILD; COMPARATIVE STUDY; IMMUNOLOGY; LYMPH NODE; LYMPHOCYTE; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CHILD; FEMALE; HISTIOCYTES; HUMANS; IMMUNOGLOBULIN D; IMMUNOPHENOTYPING; LYMPH NODES; LYMPHOCYTES; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; SEX FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 33745056322     PISSN: 01475185     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pas.0000194741.87798.45     Document Type: Article

References (36)

1. Achten R, Verhoef G, Vanuytsel L, et al. T-cell/histiocyte-rich large B-cell lymphoma: a distinct clinicopathologic entity. J Clin Oncol. 2002;20:1269-1277.
2. Arpin C, de Bouteiller O, Razanajaona D, et al. Human peripheral B cell development. sIgM-IgD+CD38+ hypermutated germinal center centroblasts preferentially express Ig lambda light chain and have undergone mu-to-delta switch. Ann NY Acad Sci. 1997;815:193-198.
3. Arpin C, de Bouteiller O, Razanajaona D, et al. The normal counterpart of IgD myeloma cells in germinal center displays extensively mutated IgVH gene, Cmu-Cdelta switch, and lambda light chain expression. J Exp Med. 1998;187:1169-1178.
4. Borggrefe T, Masat L, Wabl M, et al. Cellular, intracellular, and developmental expression patterns of murine SWAP-70. Eur J Immunol. 1999;29:1812-1822.
5. Boudova L, Torlakovic E, Delabie J, et al. Nodular lymphocyte-predominant Hodgkin lymphoma with nodules resembling T-cell/histiocyte-rich B-cell lymphoma: differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich B-cell lymphoma. Blood. 2003;102:3753-3758.
6. Braeuninger A, Kuppers R, Strickler JG, et al. Hodgkin and Reed-Sternberg cells in lymphocyte predominant Hodgkin disease represent clonal populations of germinal center-derived tumor B cells. Proc Natl Acad Sci USA. 1997;94:9337-9342.
7. Browne P, Petrosyan K, Hernandez A, et al. The B-cell transcription factors BSAP, Oct-2, and BOB.1 and the pan-B-cell markers CD20, CD22, and CD79a are useful in the differential diagnosis of classic Hodgkin lymphoma. Am J Clin Pathol. 2003;120:767-777.
8. Carbone A, Gaidano G, Gloghini A, et al. Differential expression of BCL-6, CD138/syndecan-1, and Epstein-Barr virus-encoded latent membrane protein-1 identifies distinct histogenetic subsets of acquired immunodeficiency syndrome-related non-Hodgkin's lymphomas. Blood. 1998;91:747-755.
9. Chan WC. Cellular origin of nodular lymphocyte-predominant Hodgkin's lymphoma: immunophenotypic and molecular studies. Semin Hematol. 1999;36:242-252.
10. Delsol G, Al Saati T, Gatter KC, et al. Coexpression of epithelial membrane antigen (EMA), Ki-1, and interleukin-2 receptor by anaplastic large cell lymphomas: diagnostic value in so-called malignant histiocytosis. Am J Pathol. 1988;130:59-70.
11. Dogan A, Du MQ, Aiello A, et al. Follicular lymphomas contain a clonally linked but phenotypically distinct neoplastic B-cell population in the interfollicular zone. Blood. 1998;91:4708-4714.
12. Falini B, Bigerna B, Pasqualucci L, et al. Distinctive expression pattern of the BCL-6 protein in nodular lymphocyte predominance Hodgkin's disease. Blood. 1996;87:465-471.
13. Fan Z, Natkunam Y, Bair E, et al. Characterization of variant patterns of nodular lymphocyte predominant Hodgkin lymphoma with immunohistologic and clinical correlation. Am J Surg Pathol. 2003;27:1346-1356.
14. Greiner A, Tobollik S, Buettner M, et al. Differential expression of activation-induced cytidine deaminase (AID) in nodular lymphocyte-predominant and classical Hodgkin lymphoma. J Pathol. 2005;205:541-547.
15. Hansmann ML, Stein H, Dallenbach F, et al. Diffuse lymphocyte-predominant Hodgkin's disease (diffuse paragranuloma): a variant of the B-cell-derived nodular type. Am J Pathol. 1991;138:29-36.
16. Heerema AE, Abbey NW, Weinstein M, et al. Expression of the diffuse B-cell lymphoma family molecule SWAP-70 in human B-cell neoplasms: immunohistochemical study of 86 cases. Appl Immunohistochem Mol Morphol. 2004;12:21-25.
17. Jundt F, Kley K, Anagnostopoulos I, et al. Loss of PU.1 expression is associated with defective immunoglobulin transcription in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease. Blood. 2002;99:3060-3062.
18. Kerim S, Reato G, Abele C, et al. Immunoglobulin light chain restriction and clonal rearrangement in nodular paragranuloma. Leuk Lymphoma. 1994;14:515-520.
19. Klein U, Rajewsky K, Kuppers R. Human immunoglobulin (Ig)M+IgD+ peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells. J Exp Med. 1998;188:1679-1689.
20. Liu YJ, Arpin C, de Bouteiller O, et al. Sequential triggering of apoptosis, somatic mutation and isotype switch during germinal center development. Semin Immunol. 1996;8:169-177.
21. Liu YJ, de Bouteiller O, Arpin C, et al. Normal human IgD+IgM-germinal center B cells can express up to 80 mutations in the variable region of their IgD transcripts. Immunity. 1996;4:603-613.
22. Loddenkemper C, Anagnostopoulos I, Hummel M, et al. Differential Emu enhancer activity and expression of BOB.1/OBF.1, Oct2, PU.1, and immunoglobulin in reactive B-cell populations, B-cell non-Hodgkin lymphomas, and Hodgkin lymphomas. J Pathol. 2004;202:60-69.
23. Marafioti T, Hummel M, Anagnostopoulos I, et al. Origin of nodular lymphocyte-predominant Hodgkin's disease from a clonal expansion of highly mutated germinal-center B cells. N Engl J Med. 1997;337:453-458.
24. Marafioti T, Mancini C, Ascani S, et al. Leukocyte-specific phosphoprotein-1 and PU.1: two useful markers for distinguishing T-cell-rich B-cell lymphoma from lymphocyte-predominant Hodgkin's disease. Haematologica. 2004;89:957-964.
25. Ohno T, Stribley JA, Wu G, et al. Clonality in nodular lymphocyte-predominant Hodgkin's disease. N Engl J Med. 1997;337:459-465.
26. Pernis B, Forni L. IgD receptors of lymphoid cells. Immunol Commun. 1976;5:807-826.
27. Ripp JA, Loiue DC, Chan W, et al. T-cell rich B-cell lymphoma: clinical distinctiveness and response to treatment in 45 patients. Leuk Lymphoma. 2002;43:1573-1580.
28. Rudiger T, Gascoyne RD, Jaffe ES, et al. Workshop on the relationship between nodular lymphocyte predominant Hodgkin's lymphoma and T cell/histiocyte-rich B cell lymphoma. Ann Oncol. 2002;13(Suppl 1):44-51.
29. Schmid C, Sargent C, Isaacson PG. L and H cells of nodular lymphocyte predominant Hodgkin's disease show immunoglobulin light-chain restriction. Am J Pathol. 1991;139:1281-1289.
30. Sextro M, Diehl V, Franklin J, et al. Lymphocyte predominant Hodgkin's disease: a workshop report. European Task Force on Lymphoma. Ann Oncol. 1996;7(Suppl 4):61-65
31. Stein H, Marafioti T, Foss HD, et al. Down-regulation of BOB.1/OBF.1 and Oct2 in classical Hodgkin disease but not in lymphocyte predominant Hodgkin disease correlates with immunoglobulin transcription. Blood. 2001;97:496-501.
32. Torlakovic E, Tierens A, Dang HD, et al. The transcription factor PU.1, necessary for B-cell development is expressed in lymphocyte predominance, but not classical Hodgkin's disease. Am J Pathol. 2001;159:1807-1814.
33. Tsirigotis P, Economopoulos T, Rontogianni D, et al. T-cell-rich B-cell lymphoma: analysis of clinical features, response to treatment, survival and comparison with diffuse large B-cell lymphoma. Oncology. 2001;61:257-264.
34. Uherova P, Valdez R, Ross CW, et al. Nodular lymphocyte predominant Hodgkin lymphoma: an immunophenotypic reappraisal based on a single-institution experience. Am J Clin Pathol. 2003;119:192-198.
35. van der Burg M, Bende RJ, Aarts WM, et al. Biased Ig lambda expression in hypermutated IgD multiple myelomas does not result from receptor revision. Leukemia. 2002;16:1358-1361.
36. Wlodarska I, Nooyen P, Maes B, et al. Frequent occurrence of BCL6 rearrangements in nodular lymphocyte predominance Hodgkin lymphoma but not in classical Hodgkin lymphoma. Blood. 2003;101:706-710.